Dermatology

We support the scientific advancement

of your Skin and Hair Therapeutic products

Are you seeking validated or innovative efficacy assays? Do you need to characterize active ingredients, demonstrate the activity of your dermatological formulations, or test product safety early on?

At QIMA Life Sciences, our expert team is dedicated to advancing your drug development pipeline and helping you achieve your objectives.

Access to Extensive Biobank Resources

Our unique access to healthy and diseased hair and skin samples, sourced through our network of dermatologists and plastic surgeons, is a key advantage. These samples are used to identify targets using state of the art techniques, isolate pathological cells, and run securely stored in our Biobank ex vivo organ culture.

Comprehensive Preclinical and Clinical Research for Advancing Candidates Through Clinical Trials

We provide state-of-the-art preclinical and clinical research services for skin and hair diseases, covering the entire product development journey. Our preclinical services include in vitro and ex vivo compound screening, in vivo efficacy testing, MOA elucidation, and more. We also offer advanced co-culture models.

Drug candidates identified in preclinical research can be further validated through clinical trials in our dedicated hair clinical trial unit or via strategic partnerships. We specialize in evaluating the efficacy and safety of ingredients for skin and hair disorder management.

Customized Study Projects and Expert Consulting

We offer consulting services to help you select the right experimental models and tailor your study projects. Regular communication and progress updates are integral to our approach. Our services are designed to help you meet your preclinical research goals efficiently.

With expertise in in vitro and ex vivo models and skin physiology, we support your development projects and validate your products, ensuring success in a competitive landscape.

Preclinical & Clinical Research in Dermatology

We can support you with:

We offer state-of-the-art techniques, e.g. (single cell) RNAseq, laser capture microdissection, applied to healthy and diseased tissue samples and pre-clinical models to identify novel targets in skin and hair disorders that can be modulated by pharmaceutical, cosmeceutical or nutraceutical compounds.

We offer state-of-the-art techniques, e.g. in situ hybridization, multiplex immunostainings, applied to healthy and diseased tissue samples and pre-clinical models to examine the source, expression and localization of your target of interest in healthy and diseased skin and hair samples.

We offer pre-clinical models, and state-of-the-art techniques, including gene silencing ex vivo, to study if modulation of your target of interest provides an efficient therapeutic benefit on skin and hair pathology within an acceptable safety window.

We offer pre-clinical models to identify the underlying molecular mechanisms in skin and hair samples addressed by your target.

We use state-of-the-art techniques and pre-clinical models, including organ culture of diseased skin samples to identify and establish biomarkers as early indicators for skin and hair disease progression.

We use pre-clinical models, including organ culture of diseased skin samples, to predict treatment responses induced by your target of interest, in skin and hair pathologies.

We offer pre-clinical models to examine the efficacy and safety of your compound on targets of interest in comparison to well known agents.

We offer pre-clinical models to test if the modulation of your target of interest efficiently affects skin and hair biology, ameliorates experimentally-induced pathological conditions or the phenotype of diseased samples.

We offer pre-clinical models to investigate the localization and distribution of your compound/drug/nutraceutical in skin and hair samples to support the selection of best mode or vehicle for administration.

We are happy to help you in customizing assays to optimally meet your research needs, and to join forces to establish clinically-meaningful models.
We are constantly working on the establishment of new assays,

Latest Insights

SCIENTIFIC NEWS & AGENDA